| EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers (NCT05176665) | Shanghai EpimAb Biotherapeutics Co., Ltd. | 2021-10-21 |
| ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer (NCT04602117) | QuantumLeap Healthcare Collaborative | 2021-07-28 |
| Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors (NCT02259725) | University of Southern California | 2016-08-16 |
| Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors (NCT01155258) | University of Southern California | 2010-06-01 |
| Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (NCT00397384) | National Cancer Institute (NCI) | 2007-01-01 |
| Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors (NCT00131911) | National Cancer Institute (NCI) | 2005-06-01 |
| Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (NCT00655655) | Mayo Clinic | 2004-12-01 |
| EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer (NCT00087191) | National Cancer Institute (NCI) | 2004-05-01 |
| Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors (NCT00084461) | National Cancer Institute (NCI) | 2004-03-01 |
| Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma (NCT00093782) | National Cancer Institute (NCI) | 2003-12-01 |
| Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors (NCT00075439) | National Cancer Institute (NCI) | 2003-12-01 |
| Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors (NCT00055809) | National Cancer Institute (NCI) | 2003-01-01 |
| 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) (NCT00031681) | National Cancer Institute (NCI) | 2001-12-01 |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (NCT00004074) | National Cancer Institute (NCI) | 1999-08-01 |